Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study

NCT00990535 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT00990535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00990535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study
Lead sponsor
Federico II University
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
December 31, 2008
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neoplasms, multiple endocrine neoplasia, pancreatic neoplasms, respiratory tract neoplasms, thymic neoplasms